Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan;11(1):e006397.
doi: 10.1136/jitc-2022-006397.

Next-generation ctDNA-driven clinical trials in precision immuno-oncology

Charu Aggarwal  1 , Natasha B Leighl  2
Affiliations
Comment

Next-generation ctDNA-driven clinical trials in precision immuno-oncology

Charu Aggarwal et al. J Immunother Cancer. 2023 Jan.
No abstract available

Keywords: biomarkers, tumor.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CA reports receiving institutional research funding from AstraZeneca, Genentech, Incyte, Macrogenics, Medimmune, and Merck Sharp & Dohme, and receiving consultation fees from Genentech, Lilly, Celgene Merck, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo/AstraZeneca, Regeneron/Sanofi, Eisai, BeiGene, Turning Point, Pfizer, Janssen, Boehringer Ingelheim. NBL declares institutional research funding from Amgen, Array, AZ, Bayer, BMS, Eli Lilly, EMD Serono, Guardant Health, Inivata, Janssen, MSD, Novartis, Pfizer, Roche, Takeda and honoraria and/or travel support for independent CME lectures from Amgen, BMS, EMD Serono, MSD, Novartis, Regeneron, Roche, Sanofi Genzyme, Takeda.

Comment on

References

    1. Sivapalan L, Murray J, Canzoniero J. Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. J Immunother Cancer 2022; - PMC - PubMed
    1. Anagnostou V, Forde PM, White JR, et al. . Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res 2019;79:1214–25. 10.1158/0008-5472.CAN-18-1127 - DOI - PMC - PubMed
    1. Thompson JC, Carpenter EL, Silva BA, et al. . Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving Pembrolizumab-Based therapy. JCO Precis Oncol 2021;510.1200/PO.20.00321. [Epub ahead of print: 19 03 2021]. - DOI - PMC - PubMed
    1. Vega DM, Nishimura KK, Zariffa N, et al. . Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. JCO Precis Oncol 2022;6:e2100372. 10.1200/PO.21.00372 - DOI - PMC - PubMed
    1. Zhou C, Das Thakur M, Srivastava MK, et al. . 2O IMpower010: biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. Annals of Oncology 2021;32:S1374–91. 10.1016/j.annonc.2021.10.018 - DOI

Substances